HBA-JRA H.B. 1719 76(R) BILL ANALYSIS Office of House Bill AnalysisH.B. 1719 By: Dukes Public Health 3/18/1999 Introduced BACKGROUND AND PURPOSE Currently, gamma butyrolactone, Androstenedione, and 19-Norandrostenedione are not classified as controlled substances and are being sold over-the-counter as diet supplements, under the brandnames Revivarant, Revivarant G, and Epiandostenone. These drugs may be dangerous and addictive. H.B. 1719 classifies gamma butyrolactone as a Schedule I controlled substance, and classifies Androstenedione and 19-Norandrostenedione as Schedule III controlled substances. RULEMAKING AUTHORITY It is the opinion of the Office of House Bill Analysis that this bill does not expressly delegate any additional rulemaking authority to a state officer, department, agency, or institution. SECTION BY SECTION ANALYSIS SECTION 1. Amends Subchapter B, Chapter 481, Health and Safety Code, by adding Section 481.037, as follows: Sec. 481.037. DESIGNATION OF CERTAIN SUBSTANCES. Provides that Schedule I includes gamma butyrolactone and Schedule III includes Androstenedione and 19Norandrostenedione, notwithstanding any other provision of this subchapter (Schedules) and prohibits the commissioner of public health or the commissioner's designee from modifying Schedule I or Schedule III to exclude these substances, notwithstanding Sections 481.032(a) (Schedules) and 481.034 (Establishment and Modification of Schedules by Commissioner), Health and Safety Code. SECTION 2. Effective date: September 1, 1999. SECTION 3. Emergency clause.